Профілактика перинатальної передачі ВІЛ — the 5-stage PMTCT cascade from antepartum maternal ART through confirmed infant status
Perinatal HIV transmission prevention (PMTCT) begins with the mother's own viral suppression. Combination antiretroviral therapy (ART), started as early as possible in pregnancy — or continued without interruption if the mother is already on treatment — drives plasma HIV RNA toward undetectable levels. Because maternal viral load is the dominant predictor of transmission risk at every subsequent stage (intrapartum exposure, delivery mode, even breastfeeding), early and sustained antepartum suppression is the foundation on which the rest of the cascade is built.
HIV crosses the maternal-fetal interface primarily in proportion to the amount of virus circulating in maternal blood and genital secretions. Transplacental transmission, exposure to maternal blood and secretions during labor, and exposure via breast milk are all strongly correlated with plasma HIV RNA concentration.
A mother with a durably undetectable viral load transmits the virus perinatally in well under 1% of pregnancies in modern cohorts, whereas an untreated mother with high viremia faces transmission risk in the range of roughly 15–45% depending on additional factors (duration of ruptured membranes, delivery mode, breastfeeding practices, maternal immune status). This dose-response relationship is the reason every subsequent decision in the cascade — IV zidovudine, delivery mode, infant prophylaxis intensity — is keyed off maternal viral load near delivery.
Earlier ART initiation matters because viral suppression is not instantaneous: it typically takes several weeks of adherent therapy to drive HIV RNA below the limit of quantification, and durable suppression sustained across weeks is what protects the infant, not a single low reading.
Recommended first-line regimens in pregnancy generally combine two nucleoside/nucleotide reverse transcriptase inhibitors with an integrase strand transfer inhibitor, chosen for a strong safety record, high potency, and rapid viral decline. Regimen selection also weighs pill burden, drug-drug interactions, and known safety data across trimesters, since pregnancy is a time when medication adherence can be uniquely challenged by nausea, fatigue, stigma, and disclosure concerns.
Routine antenatal care for a person living with HIV therefore layers standard obstetric visits with viral load monitoring roughly every trimester and again close to delivery, adherence counseling, and coordinated support so that treatment interruptions — which allow viral rebound — are avoided.
Women who are already virologically suppressed when they become pregnant are generally continued on their existing effective regimen rather than switched, since switching itself can risk transient viremia during the transition.
The relationship between antepartum ART duration and transmission risk is not linear — most of the protective benefit accrues once durable suppression is achieved and sustained through delivery, which is why both "how long on ART" and "how suppressed at delivery" are tracked together rather than either factor alone.
Labor and delivery represent a period of substantial infant exposure to maternal blood and genital secretions, making intrapartum management a critical checkpoint. Oral maternal ART is continued without interruption through labor. For mothers whose viral load is not well-controlled close to delivery, intravenous zidovudine infusion is considered as an additional layer of protection, alongside obstetric practices designed to minimize unnecessary exposure.
Intravenous zidovudine during labor was one of the earliest and most impactful PMTCT interventions, historically cutting transmission substantially even before modern combination ART existed. In the current era of effective antepartum ART, IV zidovudine is selectively added — rather than given universally — targeted at mothers whose viral load near delivery is elevated (roughly above the 1000 copies/mL range) or unknown, since these are the situations where residual transmission risk remains meaningfully higher.
For mothers with a well-documented, durably suppressed viral load on a stable regimen, guidelines increasingly support omitting IV zidovudine given the very low incremental benefit relative to the burden of an additional infusion during labor. This individualized approach reflects a shift from blanket prophylaxis toward viral-load-stratified, risk-adapted care.
Beyond pharmacologic prophylaxis, several routine obstetric practices are adjusted to reduce infant exposure to maternal blood and secretions when maternal viral suppression is uncertain:
• Avoiding invasive fetal monitoring (fetal scalp electrodes, scalp pH sampling) that breach fetal skin and create a portal for maternal blood contact • Avoiding artificial rupture of membranes when possible, and minimizing the duration of ruptured membranes — prolonged rupture is independently associated with increased transmission risk • Avoiding routine episiotomy and minimizing operative vaginal delivery (forceps, vacuum) that can cause fetal trauma and mixing of blood • Standard universal precautions for all birth attendants, as for any delivery
These measures are layered on top of, not instead of, viral suppression — they matter most when maternal viral load near delivery is not optimally controlled.
Continuous maternal ART through labor is non-negotiable even when IV zidovudine is added: interrupting oral therapy at exactly the moment of highest exposure risk would undermine the suppression achieved during the antepartum period.
Delivery mode is one of the few PMTCT decisions made jointly by obstetric and infectious disease teams well before labor begins, because it must be scheduled. Scheduled (pre-labor) cesarean delivery meaningfully reduces intrapartum transmission risk when maternal viral load is not well-suppressed near delivery — but it carries its own surgical risks and offers little additional benefit when viral suppression is already excellent, so the decision is individualized rather than universal.
The rationale for scheduled cesarean delivery is mechanical: performing the surgery before labor begins and before membranes rupture avoids the infant's prolonged exposure to maternal genital secretions and blood that occurs during vaginal birth. This benefit is largest exactly when maternal viral load is elevated, because more circulating and locally shed virus means more exposure risk per unit of time in the birth canal.
When maternal viral load near delivery is well-suppressed (generally interpreted as durably below roughly 1000 copies/mL, and ideally undetectable), the incremental transmission-risk reduction from scheduled cesarean becomes very small, while the maternal risks of major abdominal surgery — bleeding, infection, longer recovery, risks in future pregnancies — remain unchanged. For this reason, vaginal delivery is considered reasonable and is not discouraged when suppression is well documented.
The decision is therefore explicitly viral-load-stratified rather than a blanket recommendation, and is revisited as the most recent viral load result becomes available close to the expected delivery date.
When scheduled cesarean is recommended, it is typically planned at approximately 38 weeks gestation — early enough to occur before spontaneous labor or rupture of membranes in most pregnancies, since either event before a planned procedure diminishes its protective benefit.
The decision also incorporates standard obstetric considerations independent of HIV status (fetal presentation, prior cesarean, other pregnancy complications) and is made collaboratively with the patient, since it involves weighing a modest but real reduction in transmission risk against surgical recovery, future pregnancy considerations, and personal preference.
Delivery mode decisions hinge on the most recent viral load result close to term, not on viral load measured earlier in pregnancy — a mother who started ART late but achieves suppression by the time of delivery may still be a reasonable candidate for vaginal delivery.
Every infant born to a mother with HIV receives postnatal antiretroviral prophylaxis, initiated as soon as possible after birth. The specific regimen — a single drug versus a multi-drug combination, and for how many weeks — is tailored to the infant's risk of having acquired HIV, which is driven primarily by whether maternal viral suppression was well documented and adequate throughout pregnancy and around delivery.
Infant prophylaxis intensity follows directly from the risk stratification built up over the preceding stages of the cascade:
• Standard (low-risk) prophylaxis is used when the mother received antepartum ART for an adequate duration and achieved and maintained viral suppression through pregnancy and delivery. In this scenario, a single antiretroviral drug given for approximately four weeks provides sufficient additional protection given the already very low baseline risk.
• Enhanced (higher-risk) multi-drug prophylaxis is used when maternal viral suppression was not documented, was inadequate, or ART was started late or interrupted — situations where the infant's risk of in-utero or intrapartum acquisition is higher. A combination of two or three antiretroviral drugs, generally for a longer duration, provides a stronger prophylactic effect analogous to post-exposure prophylaxis in other settings.
This stratification means the same newborn examination and physical presentation can lead to different prophylaxis plans purely based on the maternal ART and virologic history reviewed at delivery.
Prophylaxis is started as soon as possible after birth — ideally within the first several hours — since its protective effect depends on establishing drug levels before any residual virus present at birth has the opportunity to establish infection in infant cells.
Infants receiving multi-drug enhanced prophylaxis require closer laboratory monitoring during the prophylaxis course (for example, blood counts, given known hematologic effects of some agents), and caregivers are counseled on the importance of completing the full prescribed duration even though the infant appears entirely well, since prophylaxis is preventive rather than treating an established diagnosis.
Infant prophylaxis is a bridge, not a diagnosis: an infant on enhanced multi-drug prophylaxis is not presumed to have HIV — the regimen reflects elevated risk of exposure, and definitive status is established only through the virologic testing schedule that follows.
The PMTCT cascade concludes with a structured schedule of infant virologic testing designed to reliably confirm HIV status over the first months of life, combined with feeding counseling that reflects current guidelines and the resources available to the family. Because standard antibody tests are unreliable in HIV-exposed infants (maternal antibodies persist for months), diagnosis relies on direct virologic (nucleic acid) testing at defined intervals.
Maternal HIV antibodies cross the placenta and persist in an HIV-exposed infant's circulation for many months after birth, regardless of whether the infant actually acquired HIV. A standard antibody test in an exposed infant would therefore be positive in essentially all cases early in life, making it useless for diagnosis in this population.
Instead, diagnosis relies on tests that directly detect the virus itself — nucleic acid amplification testing (NAT) for HIV DNA or RNA — which reflects the infant's own infection status rather than passively transferred maternal antibody. A structured testing schedule is followed: an initial test in the first weeks of life, with additional confirmatory testing at subsequent defined intervals, since a single early negative result cannot fully exclude infection (particularly intrapartum-acquired infection, which may not yet be detectable immediately after birth).
A sequence of negative virologic tests obtained after completion of prophylaxis, spaced appropriately, allows clinicians to presumptively and then definitively exclude HIV infection in the infant. Only an eventual antibody test at 18+ months (after maternal antibody has cleared) provides final serologic confirmation.
Feeding guidance for infants born to mothers with HIV differs substantially depending on the resource setting and current viral suppression status, and is one of the more context-dependent elements of the cascade:
• In settings with reliable access to safe replacement feeding, avoidance of breastfeeding has historically eliminated the additional postnatal transmission risk associated with breast milk exposure, and formula feeding may be recommended or preferred.
• In settings where replacement feeding carries its own significant risks (unsafe water, malnutrition, stigma, lack of access), guidelines support exclusive breastfeeding with maternal ART adherence and viral suppression maintained throughout the breastfeeding period, alongside continued infant follow-up, since the mortality and morbidity risks of not breastfeeding in those contexts can outweigh the now-substantially-reduced transmission risk from a virally suppressed mother.
In all settings, the guiding principle is the same: maternal viral suppression should be sustained for as long as breastfeeding continues, and feeding decisions are made collaboratively with the family based on current guidance rather than a single universal rule.
A negative infant HIV test is not the end of counseling — sustained maternal viral suppression, adherence support, and continued pediatric follow-up through the full testing and, where applicable, breastfeeding period remain essential to keeping that result durably negative.